|
US7013219B2
(en)
*
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US20030104526A1
(en)
*
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
|
CA2394850C
(en)
*
|
1999-12-06 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
|
US20020055112A1
(en)
*
|
2000-08-26 |
2002-05-09 |
Nila Patil |
Methods for reducing complexity of nucleic acid samples
|
|
US20020164634A1
(en)
*
|
2000-08-26 |
2002-11-07 |
Perlegen Sciences, Inc. |
Methods for reducing complexity of nucleic acid samples
|
|
CA2434881A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Method for identifying functional nucleic acids
|
|
JP4128955B2
(ja)
*
|
2001-08-17 |
2008-07-30 |
トゥールゲン・インコーポレイテッド |
ジンクフィンガードメインライブラリー
|
|
CA2469477A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
AU2003215094B2
(en)
*
|
2002-02-07 |
2008-05-29 |
The Scripps Research Institute |
Zinc finger libraries
|
|
US20030180777A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Victor Bartsevich |
Rapid identification of transcriptional regulatory domains
|
|
WO2004037977A2
(en)
|
2002-09-05 |
2004-05-06 |
California Institute Of Thechnology |
Use of chimeric nucleases to stimulate gene targeting
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
CA2498928A1
(en)
*
|
2002-09-12 |
2004-03-25 |
Massachusetts Institute Of Technology |
Rb pathway and chromatin remodeling genes that antagonize let-60 ras signaling
|
|
US20070178454A1
(en)
*
|
2002-10-21 |
2007-08-02 |
Joung J K |
Context sensitive paralell optimization of zinc finger dna binding domains
|
|
US20060246440A1
(en)
*
|
2002-10-23 |
2006-11-02 |
Joung J K |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
|
US20060166206A1
(en)
*
|
2002-11-15 |
2006-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
|
AU2003302752A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Toolgen, Inc. |
Regulatory zinc finger proteins
|
|
US20060183132A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20090124514A1
(en)
*
|
2003-02-26 |
2009-05-14 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20050100911A1
(en)
*
|
2003-08-06 |
2005-05-12 |
Perlegen Sciences, Inc. |
Methods for enriching populations of nucleic acid samples
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005287278B2
(en)
*
|
2004-09-16 |
2011-08-04 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
JP5237799B2
(ja)
|
2005-06-27 |
2013-07-17 |
エグゼリクシス パテント カンパニー エルエルシー |
ピラゾールベースのlxrモジュレーター
|
|
US7718131B2
(en)
*
|
2005-07-06 |
2010-05-18 |
Genetix Limited |
Methods and apparatus for imaging and processing of samples in biological sample containers
|
|
US20070148674A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Wisconsin Alumni Research Foundation (Warf) |
Optical fingerprinting of nucleic acid sequences
|
|
WO2007106603A2
(en)
*
|
2006-01-06 |
2007-09-20 |
The Scripps Research Institute |
Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
|
|
KR100756055B1
(ko)
*
|
2006-01-27 |
2007-09-07 |
연세대학교 산학협력단 |
신생혈관 생성을 조절하는 재조합 아데노바이러스
|
|
WO2007106488A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Wyeth |
Modulators of gluconeogenesis
|
|
EP2018424A2
(de)
*
|
2006-05-19 |
2009-01-28 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur deaktivierung von dihydrofolat-reduktase
|
|
EP2019839B1
(de)
|
2006-05-25 |
2011-12-07 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur gendeaktivierung
|
|
DE602007005634D1
(de)
|
2006-05-25 |
2010-05-12 |
Sangamo Biosciences Inc |
Variante foki-spaltungshälften-domänen
|
|
CA2660485C
(en)
|
2006-08-11 |
2016-04-12 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease-mediated homologous recombination
|
|
US9217026B2
(en)
*
|
2006-11-13 |
2015-12-22 |
Sangamo Biosciences, Inc. |
Method of inactivating a glucocorticoid receptor gene in an isolated cell
|
|
CN101883850B
(zh)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
用于失活α-1,6岩藻糖基转移酶(FUT8)基因表达的方法和组合物
|
|
AU2008305590A1
(en)
*
|
2007-09-27 |
2009-04-02 |
Sangamo Therapeutics, Inc. |
Genomic editing in zebrafish using zinc finger nucleases
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
DK2205749T3
(en)
*
|
2007-09-27 |
2016-08-22 |
Dow Agrosciences Llc |
MODIFIED PROTEINS zinc finger, which target the 5-enolpyruvylshikimate-3-phosphate synthase genes
|
|
CA2703045C
(en)
|
2007-10-25 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
WO2009146179A1
(en)
*
|
2008-04-15 |
2009-12-03 |
University Of Iowa Research Foundation |
Zinc finger nuclease for the cftr gene and methods of use thereof
|
|
JP5763530B2
(ja)
|
2008-06-10 |
2015-08-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Bax−およびBak−欠損細胞株の生成のための方法および組成物
|
|
SG191561A1
(en)
|
2008-08-22 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
CN102264915B
(zh)
|
2008-10-29 |
2014-04-16 |
桑格摩生物科学股份有限公司 |
失活谷氨酰胺合成酶基因表达的方法和组合物
|
|
JP5681114B2
(ja)
|
2008-12-04 |
2015-03-04 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集
|
|
EP3354275B1
(de)
|
2009-02-04 |
2019-10-30 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von nervenleiden
|
|
AU2010226313B2
(en)
*
|
2009-03-20 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Modification of CXCR4 using engineered zinc finger proteins
|
|
JP6215533B2
(ja)
|
2009-04-09 |
2017-10-18 |
サンガモ セラピューティクス, インコーポレイテッド |
幹細胞への標的組込み
|
|
US9234016B2
(en)
*
|
2009-07-28 |
2016-01-12 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for treating trinucleotide repeat disorders
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
NZ601247A
(en)
*
|
2010-01-22 |
2014-10-31 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
|
DK2534173T3
(da)
|
2010-02-08 |
2019-10-14 |
Sangamo Therapeutics Inc |
Manipulerede spaltnings-halvdomæner
|
|
EP2534163B1
(de)
*
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Gezielte genommodifikation mit partiell einsträngigen donatormolekülen
|
|
KR101880536B1
(ko)
|
2010-04-26 |
2018-07-23 |
상가모 테라퓨틱스, 인코포레이티드 |
아연 핑거 뉴클레아제를 사용하는 로사 좌위의 게놈 편집
|
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス, インコーポレイテッド |
新規のdna結合タンパク質及びその使用
|
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
CN103270046B
(zh)
|
2010-10-12 |
2016-05-11 |
费城儿童医院 |
治疗b型血友病的方法和组合物
|
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
AU2012284365B2
(en)
|
2011-07-15 |
2017-04-20 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
EP2734621B1
(de)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Beurteilung und verbesserung einer nukleasespaltungsspezifität
|
|
WO2013016446A2
(en)
|
2011-07-25 |
2013-01-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA2852955C
(en)
|
2011-10-27 |
2021-02-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
JP6144691B2
(ja)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
修飾されたdna結合タンパク質およびその使用
|
|
NZ629427A
(en)
|
2012-02-29 |
2016-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treating huntington’s disease
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
KR102091298B1
(ko)
*
|
2012-05-02 |
2020-03-19 |
다우 아그로사이언시즈 엘엘씨 |
말산 탈수소효소의 표적화된 변형
|
|
CA2871524C
(en)
|
2012-05-07 |
2021-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
EP2872154B1
(de)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
PL2890780T3
(pl)
|
2012-08-29 |
2021-02-08 |
Sangamo Therapeutics, Inc. |
Sposoby i kompozycje do leczenia zaburzeń genetycznych
|
|
WO2014039585A2
(en)
|
2012-09-04 |
2014-03-13 |
The Scripps Research Institute |
Chimeric polypeptides having targeted binding specificity
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
BR112015004995B1
(pt)
|
2012-09-07 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Método para modificação do genoma de uma célula, uso de uma célula, semente ou planta obtida pelo referido método e nuclease de dedo de zinco sítio específica
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014059255A1
(en)
|
2012-10-12 |
2014-04-17 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
|
AU2014214719B2
(en)
|
2013-02-07 |
2020-02-13 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
IL289396B2
(en)
|
2013-03-15 |
2023-12-01 |
The General Hospital Coporation |
Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
|
|
WO2014153470A2
(en)
|
2013-03-21 |
2014-09-25 |
Sangamo Biosciences, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2908697C
(en)
|
2013-04-16 |
2023-12-12 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN105899665B
(zh)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
EP3066110B1
(de)
|
2013-11-04 |
2021-12-29 |
Corteva Agriscience LLC |
Optimale maispflanzen
|
|
EP3066202B1
(de)
|
2013-11-04 |
2021-03-03 |
Dow AgroSciences LLC |
Optimale sojabohnen-loci
|
|
KR102269769B1
(ko)
|
2013-11-04 |
2021-06-28 |
코르테바 애그리사이언스 엘엘씨 |
최적 메이즈 유전자좌
|
|
JP2016536021A
(ja)
|
2013-11-07 |
2016-11-24 |
エディタス・メディシン,インコーポレイテッド |
CRISPR関連方法および支配gRNAのある組成物
|
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
|
PL3068881T3
(pl)
|
2013-11-13 |
2019-08-30 |
Children's Medical Center Corporation |
Regulacja ekspresji genów, w której pośredniczą nukleazy
|
|
EP3080274B1
(de)
*
|
2013-12-09 |
2020-06-03 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für genom-engineering
|
|
SG10201700961TA
(en)
|
2013-12-11 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
SI3102673T1
(sl)
|
2014-02-03 |
2020-11-30 |
Sangamo Therapeutics, Inc. |
Postopki in sestavki za zdravljenje beta talasemije
|
|
AU2015218576B2
(en)
|
2014-02-24 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
ES2879373T3
(es)
|
2014-03-18 |
2021-11-22 |
Sangamo Therapeutics Inc |
Métodos y composiciones para la regulación de la expresión de proteínas de dedo de zinc
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
MX378789B
(es)
|
2014-05-08 |
2025-03-11 |
Sangamo Biosciences Inc |
Métodos y composiciones para tratar la enfermedad de huntington.
|
|
AU2015259191B2
(en)
|
2014-05-13 |
2019-03-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(de)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur nukleasekonstruktion
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
KR102425438B1
(ko)
|
2014-06-23 |
2022-07-27 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
|
EP3161128B1
(de)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur gezielten genetischen veränderung und verfahren zur verwendung
|
|
CA2955203C
(en)
|
2014-07-14 |
2022-01-04 |
Washington State University |
Nanos knock-out that ablates germline cells
|
|
WO2016011210A2
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
KR102455807B1
(ko)
|
2014-10-01 |
2022-10-18 |
더 제너럴 하스피탈 코포레이션 |
뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
|
|
EP3221457B1
(de)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur gezielten genmodifikation unter verwendung von gepaarten führungs-rns
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
|
EP3247366A4
(de)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur identifizierung hochspezifischer nukleasen
|
|
ES2959608T3
(es)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composición y métodos de edición del genoma de células B
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
EP3294866A4
(de)
|
2015-05-12 |
2018-12-05 |
Sangamo Therapeutics, Inc. |
Nukleasevermittelte regulierung der genexpression
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
JP7245647B2
(ja)
|
2015-07-15 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法用の操作された細胞
|
|
EP3331355B1
(de)
|
2015-08-06 |
2024-04-03 |
The Curators of the University of Missouri |
Gegen das reproduktive und respiratorische schweinesyndromvirus (prrsv) resistente schweine und zellen mit modifizierten cd163-genen
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017044843A1
(en)
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
US10435441B2
(en)
|
2015-09-23 |
2019-10-08 |
Sangamo Therapeutics, Inc. |
HTT repressors and uses thereof
|
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
|
EP4434589A3
(de)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Entwickelte cas9-proteine für geneditierung
|
|
KR102766526B1
(ko)
|
2015-10-28 |
2025-02-13 |
상가모 테라퓨틱스, 인코포레이티드 |
간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
|
|
JP6976249B2
(ja)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス, インコーポレイテッド |
免疫を工学操作するための方法および組成物
|
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
|
MX2018007519A
(es)
|
2015-12-18 |
2019-09-04 |
Sangamo Therapeutics Inc |
Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
|
|
ES2895430T3
(es)
|
2016-01-15 |
2022-02-21 |
Univ Minnesota |
Métodos y composiciones para el tratamiento de enfermedad neurológica
|
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
|
MX388294B
(es)
|
2016-05-27 |
2025-03-19 |
Aadigen Llc |
Peptidos y nanoparticulas para suministro intracelular de moleculas editoras de genoma.
|
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
CR20190098A
(es)
|
2016-08-24 |
2019-04-30 |
Sangamo Therapeutics Inc |
Regulación de la expresión génica usando nucleasas modificadas
|
|
WO2018049009A2
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
AU2017340634B2
(en)
|
2016-10-05 |
2022-06-02 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
|
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
CN110290813A
(zh)
|
2016-10-14 |
2019-09-27 |
通用医疗公司 |
表观遗传学调控的位点特异性核酸酶
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
JP7042263B2
(ja)
|
2016-10-20 |
2022-03-25 |
サンガモ セラピューティクス, インコーポレイテッド |
ファブリー病の治療のための方法および組成物
|
|
EP3532106A4
(de)
|
2016-10-31 |
2020-06-24 |
Sangamo Therapeutics, Inc. |
Genkorrektur von scid-assoziierten genen bei hämotopoietischen stammzellen und vorläuferzellen
|
|
KR102674612B1
(ko)
|
2016-12-01 |
2024-06-14 |
상가모 테라퓨틱스, 인코포레이티드 |
Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
|
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
|
CN110249051A
(zh)
|
2016-12-08 |
2019-09-17 |
凯斯西储大学 |
增强功能性髓鞘产生的方法和组合物
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
CA3058189A1
(en)
|
2017-04-03 |
2018-10-11 |
Encoded Therapeutics, Inc. |
Tissue selective transgene expression
|
|
DK3615674T3
(da)
|
2017-04-28 |
2024-06-17 |
Univ Colorado Regents |
Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
EP3630970A4
(de)
|
2017-05-25 |
2020-12-30 |
The General Hospital Corporation |
Basiseditoren mit verbesserter präzision und spezifität
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
WO2019018383A1
(en)
|
2017-07-18 |
2019-01-24 |
Calimmune, Inc. |
COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
WO2019032675A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
CELL TARGETING MEDIATED BY A CHIMERIC ANTIGEN RECEPTOR
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
JP2021502085A
(ja)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
サイトカイン誘導性sh2含有タンパク質(cish)遺伝子の遺伝子改変
|
|
SG11202004926WA
(en)
|
2017-12-01 |
2020-06-29 |
Encoded Therapeutics Inc |
Engineered dna binding proteins
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
EA202091709A1
(ru)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
|
BR112020014315A2
(pt)
|
2018-01-17 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Inibidores de dna-pk
|
|
ES2940786T3
(es)
|
2018-01-17 |
2023-05-11 |
Vertex Pharma |
Compuestos de quinoxalinona, composiciones, métodos y kits para aumentar la eficiencia de edición del genoma
|
|
MX2020008272A
(es)
|
2018-02-08 |
2020-09-21 |
Sangamo Therapeutics Inc |
Nucleasas diseñadas específicas de blancos.
|
|
KR20210029707A
(ko)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
|
|
EP3775237A1
(de)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T-zellen, die einen rekombinanten rezeptor exprimieren, verwandte polynukleotide und verfahren
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
CN112469824A
(zh)
|
2018-05-11 |
2021-03-09 |
比姆医疗股份有限公司 |
利用可编程碱基编辑器系统编辑单核苷酸多态性的方法
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
KR102894715B1
(ko)
|
2018-08-03 |
2025-12-03 |
빔 테라퓨틱스, 인크. |
핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
|
|
KR102712986B1
(ko)
|
2018-08-23 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
AU2019344927A1
(en)
|
2018-09-18 |
2021-04-01 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (PD1) specific nucleases
|
|
EP4613367A1
(de)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
|
|
EP3860618B1
(de)
|
2018-10-02 |
2026-02-04 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur behandlung von tauopathie
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
AU2019390394C1
(en)
|
2018-11-28 |
2024-11-28 |
Forty Seven, LLC |
Genetically modified HSPCs resistant to ablation regime
|
|
WO2020132279A1
(en)
|
2018-12-19 |
2020-06-25 |
Nuclein, Llc |
Apparatus and methods for molecular diagnostics
|
|
US20220089589A1
(en)
|
2019-01-07 |
2022-03-24 |
Dana-Farber Cancer Institute, Inc. |
SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
|
EP3826664A4
(de)
|
2019-02-06 |
2022-10-26 |
Sangamo Therapeutics, Inc. |
Verfahren zur behandlung von mukopolysaccharidose typ i
|
|
US20220170013A1
(en)
|
2019-03-06 |
2022-06-02 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
WO2020205838A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Methods for the treatment of beta-thalassemia
|
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
PE20212332A1
(es)
|
2019-04-23 |
2021-12-14 |
Sangamo Therapeutics Inc |
Moduladores de la expresioon del gen de marco de lectura abierto 72 del cromosoma 9 y usos de los mismos
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
|
BR112021024055A2
(pt)
|
2019-05-29 |
2022-02-08 |
Encoded Therapeutics Inc |
Composições e métodos para a regulação seletiva de gene
|
|
WO2021022043A2
(en)
|
2019-07-30 |
2021-02-04 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
JP2022543112A
(ja)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー,インコーポレイテッド |
Dux4発現細胞およびそれらの使用
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
KR20220068222A
(ko)
|
2019-08-23 |
2022-05-25 |
사나 바이오테크놀로지, 인크. |
Cd24 발현 세포 및 이의 용도
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
LT3812472T
(lt)
|
2019-10-21 |
2023-03-10 |
Albert-Ludwigs-Universität Freiburg |
Objektyviai nešališkas tyrimas in vitro sąlygomis, skirtas vienos arba daugiau tikslinių programuojamų nukleazių ląstelėje nespecifinės sąveikos aktyvumui profiliuoti (abnoba-seq)
|
|
CA3159620A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
WO2021087358A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
IL296024A
(en)
|
2020-03-04 |
2022-10-01 |
Flagship Pioneering Innovations Vi Llc |
Methods and compositions for modulating a genome
|
|
CA3174482A1
(en)
|
2020-03-05 |
2021-09-10 |
The Regents Of The University Of California |
A method for producing plants with minimized biomass byproduct and associated plants thereof
|
|
US20230293593A1
(en)
|
2020-03-25 |
2023-09-21 |
Sana Biotechnology, Inc. |
Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
|
|
WO2021216114A1
(en)
*
|
2020-04-22 |
2021-10-28 |
Houston Gene Therapeutics Llc |
Compositions for treatment of vascular disease
|
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
|
CA3177093A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
EP4146284A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur genetischen modifizierung von zellen zur freisetzung therapeutischer proteine
|
|
CN111549061A
(zh)
*
|
2020-05-07 |
2020-08-18 |
西南大学 |
一种高通量筛选真核生物细胞响应环境极端pH的靶点基因的方法
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
JP2023526278A
(ja)
|
2020-05-13 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
EP4171616A1
(de)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
IL300516A
(en)
|
2020-08-13 |
2023-04-01 |
Sana Biotechnology Inc |
Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
MX2023005665A
(es)
|
2020-11-16 |
2023-08-01 |
Pig Improvement Co Uk Ltd |
Animales resistentes a la influenza a que tienen genes de anp32 editados.
|
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー,インコーポレイテッド |
Car-t活性を調節するための方法及び組成物
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
KR20230158476A
(ko)
|
2021-02-19 |
2023-11-20 |
빔 테라퓨틱스, 인크. |
유전자 요법을 위한 재조합 광견병 바이러스
|
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
|
EP4341390A4
(de)
|
2021-05-14 |
2025-02-19 |
Becton, Dickinson and Company |
Verfahren zur herstellung von bibliotheken zur nukleinsäuresequenzierung
|
|
JP2024518094A
(ja)
|
2021-05-14 |
2024-04-24 |
ベクトン・ディキンソン・アンド・カンパニー |
多重非バイアス核酸増幅法
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
KR20240073006A
(ko)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
동종이계 세포 요법을 위한 유전자 변형된 1차 세포
|
|
WO2023019203A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
CA3230629A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
|
JP2024533311A
(ja)
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
ゲノムを調節するための方法及び組成物
|
|
EP4419117A1
(de)
|
2021-10-22 |
2024-08-28 |
Sana Biotechnology, Inc. |
Verfahren zur züchtung allogener t-zellen mit einem transgen in einem tcr-lokus sowie zugehörige zusammensetzungen und verfahren
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CN119072319A
(zh)
|
2021-12-23 |
2024-12-03 |
萨那生物技术股份有限公司 |
用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
EP4522201A1
(de)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvoviruszusammensetzungen und verfahren zur gentherapie
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
CA3263821A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
ADVANCED CYTOSIN DESAMINASE AND DNA EDITING METHODS USING IT
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4615960A1
(de)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Verfahren zur herstellung von manipulierten immunzellen
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
EP4652271A1
(de)
|
2023-01-18 |
2025-11-26 |
The Broad Institute, Inc. |
Baseneditierungsvermitteltes durchlesen von codons mit vorzeitiger terminierung (bert)
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024187174A2
(en)
|
2023-03-09 |
2024-09-12 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
WO2024197242A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
|
|
EP4704867A1
(de)
|
2023-05-03 |
2026-03-11 |
Sana Biotechnology, Inc. |
Verfahren zur dosierung und verabreichung von manipulierten inselzellen
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025064469A1
(en)
|
2023-09-18 |
2025-03-27 |
Omega Therapeutics, Inc. |
Methods for assessing dosage for epigenetic modifying agents
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|